Intratumoral T reg cell ablation elicits NK cell–mediated control of CD8 T cell–resistant tumors
Science Immunology · 10.04.2026 · 11 (118)
DOI: 10.1126/sciimmunol.adx4411 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 10.04.2026. Verfasst von Chenyu Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA. Hauptthemen laut MEDLINE: Killer Cells, Natural, T-Lymphocytes, Regulatory, CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Science Foundation, National Institutes of Health.
Abstract (Originalsprache)
Cancer cells frequently lose major histocompatibility complex class I (MHC I) to evade CD8 T cell recognition. Natural killer (NK) cells are poised to target MHC I–deficient cancer cells, but MHC I loss alone is often insufficient to unleash fully effective NK cell responses. Here, we show that selective intratumoral (IT) ablation of regulatory T cells (T reg cells) elicited potent antitumor NK cell responses that controlled MHC I–deficient and even MHC I + cancers that expressed NKG2D ligands. T reg cells controlled the activation, maturation, and antitumor cytotoxic activity of NK cells within the tumor microenvironment. Mechanistically, depletion of IT-T reg cells relieved the inhibition of cDC2-dependent induction of IL-2 production by conventional CD4 T cells that was necessary for NK cell activation. Systemically administered antibodies that selectively depleted IT-T reg cells similarly empowered NK cell–dependent tumor control. These findings expand the breadth of T reg cell–mediated cancer immunosuppression to encompass antitumor NK cells and suggest that therapeutic targeting of T reg cells in tumors can control CD8 T cell–resistant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
- Department of Electrical Engineering and Computer Sciences, University of California, Berkeley, Berkeley, CA 94720, USA.
- Center for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
- Department of Molecular and Cellular Physiology and Howard Hughes Medical Institute, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
ORCID-Profile: Chenyu Zhang, Charles Chien, Koharu Sakiyama, Alissa Bockman, Yeara Jo, Seungwon Lee, Stephanie Silveria, Elizabeth Andrews, Abigail Mende, Allon Wagner, Michel DuPage, David Raulet
Förderung
- NCI NIH HHS
- National Science Foundation
- National Institutes of Health
- Howard Hughes Medical Institute
- Cancer Research Institute
- California Institute for Regenerative Medicine
- Gilead Sciences
- Cancer Research Coordinating Committee
Zitieren
APA
Zhang, C., Chien, C., Jurgaitytė, E., Sakiyama, K., Bockman, A., Jo, Y., Lee, S., Silveria, S., Andrews, E., Mende, A., Zhang, L., Garcia, K. C., Wagner, A., DuPage, M., & Raulet, D. (2026). Intratumoral T reg cell ablation elicits NK cell–mediated control of CD8 T cell–resistant tumors. Science Immunology, 11(118). https://doi.org/10.1126/sciimmunol.adx4411
Vancouver
Zhang C, Chien C, Jurgaitytė E, Sakiyama K, Bockman A, Jo Y, et al. Intratumoral T reg cell ablation elicits NK cell–mediated control of CD8 T cell–resistant tumors. Science Immunology. 2026;11(118). doi:10.1126/sciimmunol.adx4411
BibTeX
@article{Zhang2026,
author = {Zhang, Chenyu and Chien, Charles and Jurgaitytė, Eglė and Sakiyama, Koharu and Bockman, Alissa and Jo, Yeara and Lee, Seungwon and Silveria, Stephanie and Andrews, Elizabeth and Mende, Abigail and Zhang, Lily and Garcia, K Christopher and Wagner, Allon and DuPage, Michel and Raulet, David},
title = {Intratumoral T reg cell ablation elicits NK cell–mediated control of CD8 T cell–resistant tumors},
journal = {Science Immunology},
year = {2026},
volume = {11},
number = {118},
doi = {10.1126/sciimmunol.adx4411}
}
EUVIMED